BETTER DELIVERY. BETTER MEDICINES.

Precision Intradermal Therapeutics

One biological foundation.

Two proprietary platforms.

Leveraging the unique biology of the dermis for rapid systemic delivery and precision immune activation.

Titanium Microneedle Platform

Rapid systemic delivery without injection.

Lead asset: Zograine™ for acute migraine.

Gold Nanoparticle Platform (GNP)

Programmable immune activation through dermal antigen-presenting cells.

Applications: vaccines and oncology.

Why the Dermis?

  • Dense capillary network.

  • Rich antigen-presenting cell environment.

  • Accessible route for self-administered therapy.

LEAD ASSET:

Zograine™

Better Delivery.
Better Medicines.

Acute Migraine Treatment
Zolmitriptan titanium micro needle patch

  • 3-second application

  • Bypasses the GI tract

  • Planned NDA Submission

Development Pipeline

Biotech development progress across therapeutic programs and vaccine platforms.

Preclinical
Phase 1 / 2
Phase 3
Approval
Commercial
Zograine™
Phase 3 Complete
NDA Resubmission
COVID Vaccine
Clinical
Dengue Vaccine
Clinical
Chikungunya Vaccine
Preclinical, Phase 1 Approved
Oncology GNP
Discovery
Ebola Vaccine
Discovery

Built for Translation.

Clinical asset. Human vaccine data. GMP manufacturing.
Commercial microneedle facility.